| 4.365 -2.175 (-33.26%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.77  |
1-year : | 9.55 |
| Resists | First : | 6.65 |
Second : | 8.18 |
| Pivot price | 6.83 |
|||
| Supports | First : | 4.19 |
Second : | 3.49 |
| MAs | MA(5) : | 6.24 |
MA(20) : | 6.93 |
| MA(100) : | 7.56 |
MA(250) : | 7.27 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9 |
D(3) : | 18.2 |
| RSI | RSI(14): 10.6 |
|||
| 52-week | High : | 8.97 | Low : | 4.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LFCR ] has closed below the lower bollinger band by 38.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 140.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.49 - 6.55 | 6.55 - 6.59 |
| Low: | 4.11 - 4.17 | 4.17 - 4.2 |
| Close: | 4.3 - 4.39 | 4.39 - 4.45 |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Mon, 16 Mar 2026
Lifecore Biomedical, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LFCR) 2026-03-16 - Seeking Alpha
Mon, 16 Mar 2026
LFCR: Strong 2025 results set the stage for accelerated growth from 2027 as pipeline commercializes - TradingView
Mon, 16 Mar 2026
LFCR: Transition period saw 20% revenue growth and improved margins; strong mid-term outlook - TradingView
Mon, 16 Mar 2026
Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 37 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 76.3 (%) |
| Shares Short | 2,730 (K) |
| Shares Short P.Month | 2,530 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | -30.1 % |
| Operating Margin | -9.9 % |
| Return on Assets (ttm) | -3.1 % |
| Return on Equity (ttm) | -76.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 3.43 |
| EBITDA (p.s.) | -0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -3.44 |
| PEG Ratio | 0 |
| Price to Book value | 109.12 |
| Price to Sales | 1.26 |
| Price to Cash Flow | -793.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|